(Q80243336)
Statements
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? (English)
J O'Shaughnessy
R Leonard
S Vukelja
V Gorbounova
C A Chan-Navarro
D Maraninchi
N Barak-Wigler
J J McKendrick
W G Harker
1 September 2006